Vyvanse (Lisdexamfetamine Dimesylate) - News

News related to Vyvanse (Lisdexamfetamine) and/or conditions it is approved for

Elvanse® (Lisdexamfetamine Dimesylate) Receives UK Marketing Authorisation - New Option For The Treatment Of ADHD In Children And Adolescents
Source: ADHD News From Medical News Today [2013.02.13]
Shire plc (LSE: SHP, NASDAQ: SHPG) have announced that its single-daily dose long-acting prodrug stimulant, Elvanse, has been authorised by the MHRA for the treatment of ADHD in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.2 Elvanse is the first stimulant prodrug to be launched in Europe for the treatment of ADHD...